Compare ARDX & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | PRG |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | PRG |
|---|---|---|
| Price | $5.98 | $29.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $10.65 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.7M | 430.9K |
| Earning Date | 10-30-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | N/A | ★ 10.59 |
| EPS | N/A | ★ 3.96 |
| Revenue | $398,234,000.00 | ★ $2,507,179,000.00 |
| Revenue This Year | $22.71 | $1.32 |
| Revenue Next Year | $27.81 | $0.64 |
| P/E Ratio | ★ N/A | $7.46 |
| Revenue Growth | ★ 58.12 | 3.71 |
| 52 Week Low | $3.21 | $23.50 |
| 52 Week High | $6.78 | $48.82 |
| Indicator | ARDX | PRG |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 53.19 |
| Support Level | $5.49 | $27.48 |
| Resistance Level | $6.02 | $30.54 |
| Average True Range (ATR) | 0.28 | 1.03 |
| MACD | 0.01 | 0.37 |
| Stochastic Oscillator | 75.00 | 77.87 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.